Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

63.13 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 352
Open 63.13
Bid (Size) 63.73 (1)
Ask (Size) 64.95 (1)
Prev. Close 63.13
Today's Range 63.13 - 63.13
52wk Range 8.280 - 99.41
Shares Outstanding 99,581,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Viking Therapeutics Stock Was So Healthy on Wednesday
Hardly for the first time, a pundit following the company waxed bullish on its future. 
Via The Motley Fool
Viking Therapeutics Unusual Options Activity For September 24
Via Benzinga

Performance

YTD
+245.35%
+245.35%
1 Month
-3.65%
-3.65%
3 Month
+33.21%
+33.21%
6 Month
-24.25%
-24.25%
1 Year
+429.39%
+429.39%

More News

Read More
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stocks Stall, Gold Updates Record Highs, Tesla Rallies: What's Driving Markets Monday?
Via Benzinga
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
Via The Motley Fool
What the Options Market Tells Us About Viking Therapeutics
Via Benzinga
Viking Therapeutics Unusual Options Activity For September 11
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $7,500 Today
Via Benzinga
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
Via The Motley Fool
Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In'
Via Benzinga
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Via MarketBeat
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now.
Via The Motley Fool
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
Via Investor's Business Daily
These 2 Biotech Stocks Are Set to Soar
Via The Motley Fool
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735
Via The Motley Fool
Why Investors Plowed Into Viking Therapeutics Stock Today
Via The Motley Fool
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
Via The Motley Fool
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
Via Benzinga
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
Via Investor's Business Daily
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
Via The Motley Fool
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.